Phase 4 Completed N=75 Randomized Treatment

Conversion of Hyperglycemic Patients Being Treated With Intravenous Insulin Infusions to Lantus Insulin

Source: ClinicalTrials.gov NCT00338104 ↗

Enrolled (actual)

Serious AEs

—

Results posted

Apr 2009

Primary outcomePrimary: Percentage of Blood Glucose Values Between 80 - 140 — 43; 35; 48 percentage of blood glucose values

Summary

The primary objective of this study is to determine the optimal dose of glargine insulin when converting from intravenous short-acting continuous insulin infusions in surgical and intensive care unit patients using a prospective, controlled, parallel group, randomized study design. Note: Lantus insulin is the proprietary name for glargine insulin.

Outcome Measures

Outcome	Result	p-value
PRIMARY Percentage of Blood Glucose Values Between 80 - 140	43; 35; 48	—
SECONDARY Percentage of Glucose Values < 50 mg/dL	1; 0; 0	—
SECONDARY Percentage of Glucose Levels > 180 mg/dL	19; 34; 18	—

Eligibility Criteria

Inclusion Criteria

Fasting glucose > 100 mg/dl
Patients on surgical services or in intensive care units receiving intravenous insulin

Exclusion Criteria

Inability to obtain informed consent from patient or next-of-kin
Allergy to insulin
Participation in another research study
Patients for whom there are "do-not-resuscitate" orders

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00338104). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.